Renata PLC, a listed drug maker in Bangladesh, has launched Parkadin, the first and only registered generic version of Amantadine 100 mg capsules, in Finland, as well as in Denmark, Sweden and Norway, according to a press release.

The dopaminergic drug is used to treat symptoms of Parkinson's disease, either on its own or in combination with Levodopa, another medication for the same condition.

Parkadin will be distributed through a strategic partnership using a common pack for the Nordic region, which will enhance access to reimbursed medication and ease patients' out-of-pocket expenses.

The launch expands Renata's existing presence with Amantadine in Europe and the UK, strengthening the company's position as a global pharmaceutical manufacturer of quality medicines.

Shares of Renata rose 2.6 percent to Tk 394 at the Dhaka Stock Exchange today.